COMPASS Pathways: Accelerating Patient Access To Evidence Based Innovation In Mental Health Care
Benzinga
2023-10-05
Views 2
COMPASS Pathways (NASDAQ: CMPS) is working hard on developing innovative treatments to better help patients with an urgent unmet need. Although further research is still needed to establish its efficacy and safety, the company’s initial findings are promising and they have progressed to a phase 3 program in TRD.
The company’s innovative approach has received FDA Breakthrough Therapy designation in the U.S. and Innovative Licensing and Access Pathway designation in the UK for their investigational COMP360 psilocybin in treatment-resistant depression. Moreover, in late 2021, COMPASS Pathways announced the completion of a randomized, controlled double-blind phase 2b study of investigational COMP360 psilocybin treatment involving 233 patients with TRD in 22 sites across Europe and North America.
The company’s innovative approach has received FDA Breakthrough Therapy designation in the U.S. and Innovative Licensing and Access Pathway designation in the UK for their investigational COMP360 psilocybin in treatment-resistant depression. Moreover, in late 2021, COMPASS Pathways announced the completion of a randomized, controlled double-blind phase 2b study of investigational COMP360 psilocybin treatment involving 233 patients with TRD in 22 sites across Europe and North America.
Report form
